1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2016

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 50 pages

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2016’, provides an overview of the Microscopic Polyangiitis (MPA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA)
- The report reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Microscopic Polyangiitis (MPA) therapeutics and enlists all their major and minor projects
- The report assesses Microscopic Polyangiitis (MPA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Microscopic Polyangiitis (MPA) Overview 6
Therapeutics Development 7
Pipeline Products for Microscopic Polyangiitis (MPA) - Overview 7
Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies 8
Microscopic Polyangiitis (MPA) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Microscopic Polyangiitis (MPA) - Products under Development by Companies 12
Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development 13
ChemoCentryx, Inc. 13
Coherus BioSciences, Inc. 14
Epirus Biopharmaceuticals, Inc. 15
GlaxoSmithKline Plc 16
Panacea Biotec Limited 17
Sandoz International GmbH 18
Teijin Pharma Limited 19
Microscopic Polyangiitis (MPA) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
belimumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
CCX-168 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
immune globulin (human) - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
rituximab biosimilar - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
rituximab biosimilar - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
rituximab biosimilar - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
rituximab biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Microscopic Polyangiitis (MPA) - Recent Pipeline Updates 40
Microscopic Polyangiitis (MPA) - Dormant Projects 47
Microscopic Polyangiitis (MPA) - Product Development Milestones 48
Featured News and Press Releases 48
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 48
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables
Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx, Inc., H1 2016 13
Microscopic Polyangiitis (MPA) - Pipeline by Coherus BioSciences, Inc., H1 2016 14
Microscopic Polyangiitis (MPA) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 15
Microscopic Polyangiitis (MPA) - Pipeline by GlaxoSmithKline Plc, H1 2016 16
Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Limited, H1 2016 17
Microscopic Polyangiitis (MPA) - Pipeline by Sandoz International GmbH, H1 2016 18
Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Limited, H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Microscopic Polyangiitis (MPA) Therapeutics - Recent Pipeline Updates, H1 2016 40
Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2016 47

List of Figures
Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen ...

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016’, ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.